Ticker

Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.

FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the “Note”) with Mr.

Apollomics Inc. (NASDAQ: APLM - Get Free Report) was the target of a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 8,621 shares, a decline of 30.9% from the February 26th total of 12,471 shares. Approximately 0.8% of the shares of the company are sold

Apollomics Inc. (NASDAQ: APLM - Get Free Report) was the recipient of a large decline in short interest in the month of February. As of February 27th, there was short interest totaling 12,471 shares, a decline of 15.2% from the February 12th total of 14,705 shares. Approximately 1.1% of the company's shares are sold short. Based